Project Grant R01CA317843
- The National Cancer Institute awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $516,808 under the Cancer Treatment Research program (CFDA 93.395) on June 1, 2026, to elucidate the mechanism of targeting methionine synthase (MTR) to enhance anti-tumor immunity in KRAS-driven lung cancer. The recipient will conduct research to understand how MTR targeting enhances immune responses in KRAS-driven non-small cell lung cancer (NSCLC), which exhibits...
- The National Cancer Institute awarded the University of Rochester $814,967 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate trajectories of neurotoxicity among adolescents and young adults with Hodgkin lymphoma. The award funds research examining long-term neurotoxic effects of cancer therapy—including cancer-related cognitive impairment and peripheral and autonomic neuropathy—in this population despite the absence of central nervous...
- The National Cancer Institute awarded Rutgers The State University of New Jersey, School of Nursing, $600,871 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support a clinical research initiative examining metformin's potential to prevent chemotherapy-induced cognitive impairment in children with acute lymphoblastic leukemia. The award funds the recipient's participation in COG Protocol ACCL2432, a randomized, double-blinded Phase 3 trial comparing metformin...
- Rutgers The State University Of New Jersey, doing business as Rbhs-School Of Nursing, was awarded a $785,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund development of new therapeutic strategies for chemo brain in ovarian cancer survivors from July 1, 2023 through June 30, 2027. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform...
- The National Cancer Institute awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $599,978 under the Cancer Cause and Prevention Research program (CFDA 93.393) on July 1, 2026. The award funds a five-year prospective cohort study examining the relationship between perceived social obligations and clinical and patient-reported outcomes in 315 patients with advanced, poor-prognosis cancer. The research tests the hypothesis that higher patient-reported...
- The National Cancer Institute awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $303,431 on August 13, 2026, under the Cancer Research Manpower program (CFDA 93.398) to implement breast cancer early detection measures in primary healthcare facilities in Botswana. The award funds a five-year implementation research project guided by the Integrative Systems Praxis for Implementation Research (INSPIRE) methodology. The project will conduct key informant...
- The National Cancer Institute awarded Rutgers, The State University of New Jersey, School of Nursing $239,352 on August 11, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a sequencing-free PCR-based method for deep T-cell receptor profiling using sloppy molecular beacons in single-cell droplet digital PCR. The recipient will deliver a diagnostic technique that identifies T-cell receptor variable gene segment usage while preserving alpha-beta chain...
- The National Cancer Institute awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $170,930 under Project Grant R03CA308463 on April 1, 2026, to support research into the longitudinal dynamics of blood microbiome and circulating tumor cells in metastatic breast cancer. The research applies a novel reduced metagenomic sequencing technique to analyze longitudinal plasma samples from women with metastatic triple-negative breast cancer (MTNBC), using liquid...
- The National Cancer Institute awarded Rutgers The State University of New Jersey $672,960 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the implications of EP300 deficiency in adult T-cell leukemia/lymphoma (ATLL). The research addresses mechanisms underlying chemo-refractory ATLL in North American patients, who exhibit overall survival of only 6.9 months. The project leverages a unique collection of EP300-mutant ATLL cells and an EP300-specific PROTAC...
- The National Cancer Institute awarded a cooperative agreement to Rutgers The State University of New Jersey for $975,000 on March 21, 2026, under the Cancer Treatment Research program (CFDA 93.395). The award funds clinical trial support infrastructure and operations for the Rutgers Cancer Institute and RWJBarnabas Health System across multiple hospital sites within the health system. The award supports a centralized research administration model through the Office of Human Research Services,...
The National Cancer Institute awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $651,545 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the meningeal lymphatic system as a pathogenic driver of chemotherapy-induced cognitive impairment in cancer survivors. The research targets chemobrain, a persistent cognitive dysfunction affecting pediatric and adult cancer survivors whose underlying mechanisms remain poorly understood. The project addresses a critical gap in current understanding: how peripherally administered chemotherapeutic agents trigger neuroinflammation despite limited blood-brain barrier penetration. The recipient will examine the meningeal lymphatic system as the interface between the brain and peripheral immune system, focusing on how disruption of cerebrospinal fluid drainage and clearance of inflammatory molecules and waste promotes long-term cognitive dysfunction. Preliminary work demonstrates that DNA-damaging chemotherapeutics induce dural inflammation, disrupt meningeal lymphatic function, and impair cognitive outcomes; the research will develop disease-modifying strategies to restore meningeal lymphatic function and alleviate chemobrain using pharmacological approaches including PIEZO1 agonists. Performance occurs at Piscataway, New Jersey with a period of performance from September 1, 2026, through August 31, 2031. The assistance type is a project grant.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $651.5k | 8/27/26 |